February 18 2008 | Category: Appointment
Bunnik, The Netherlands,18 February 2008. AM-Pharma B.V., the biopharmaceutical company developing optimised endogenous proteins and peptides to combat disease, today announced the appointment of Jacques Arend as Jacques Arend, MD joined the pharmaceutical industry in 1988, in medical and clinical development positions. He started at SmithKline Beecham, and then became international coordinator clinical development with Yamanouchi Pharma’s European office. He was medical director for Novo Nordisk, where he subsequently held three international positions as director medical, regulatory and quality based in Austria, Greece and Switzerland, with responsibility over the largest geographical region in Novo Nordisk, setting up clinical studies in Europe, Latin America, Eastern Europe, India, China, South Africa, North Africa and Gulf region, the Far and Middle East. After his return to The Netherlands Jacques became medical director for Grünenthal. Most recently he was the medical director for Kendle’s phase one 50 beds Clinical Pharmacology Unit in Utrecht. Prior to his positions in the pharmaceutical industry Jacques was a clinical research physician, followed by a SHO position in Surgery.
Jacques Arend MD brings to the position a wealth of over twenty years of international experience in medical and clinical development. His previous work experience includes clinical development positions at SmithKline Beecham, Yamanouchi, Novo Nordisk, Grünenthal, with his most recent position at Kendle where he was the Medical Director for the Phase I and Clinical Pharmacology Unit.
Jacques Arend MD replaces Chief Medical Officer Luiz Porto MD, who will remain involved with AM-Pharma as Clinical Regulatory Consultant.
Bart Wuurman, CEO commented: “We are very pleased that Jacques, with his outstanding experience in clinical development, has joined our team in the key position of VP Clinical Development. During the next 18 months, we expect to finalise four Phase IIa clinical trials which aim to confirm proof of concept for two of our products and further add to the value of AM-Pharma.”
Jacques Arend added: ”The two specialist hospital care products AM-Pharma is developing have the potential to make a significant impact on the treatment of Infectious Diseases, Acute Renal Failure and Ulcerative Colitis. I am looking forward to joining AM-Pharma and assisting in the development of these products and the company’s pipeline.”